Skip to main content
Erschienen in: Drugs 12/2014

01.08.2014 | Therapy in Practice

Functional Esophageal Disorders: Pharmacological Options

verfasst von: Gehanjali Amarasinghe, Daniel Sifrim

Erschienen in: Drugs | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Functional esophageal disorders are a group of disorders that cause esophageal symptoms, although with negative results on investigation with standard esophageal tests. Therefore, structural disorders, motility disorders with a histopathological basis and gastroesophageal reflux disease (GERD) are excluded. They are frequently encountered by clinicians, and so a systematic and evidence-based approach to investigation, diagnosis and treatment are crucial. There are four functional esophageal disorders defined by the ROME III consensus, namely functional heartburn, functional chest pain, functional dysphagia and globus. Since the advent of ROME, the specification of diagnostic criteria for functional esophageal disorders has allowed more comparable studies and clinical trials. Despite this, the evidence base for many therapies in use at present is not as robust as would be desired. In this paper, we discuss the four categories of functional esophageal disorders. We then propose diagnostic algorithms based on current evidence. Finally, we discuss current therapies for each of the four functional esophageal disorders based on current evidence.
Literatur
1.
Zurück zum Zitat Galmiche JP, Clouse RE, Bálint A, Cook IJ, Kahrilas PJ, Paterson WG, et al. Functional esophageal disorders. Gastroenterology. 2006;130(5):1459–65.PubMedCrossRef Galmiche JP, Clouse RE, Bálint A, Cook IJ, Kahrilas PJ, Paterson WG, et al. Functional esophageal disorders. Gastroenterology. 2006;130(5):1459–65.PubMedCrossRef
2.
Zurück zum Zitat Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Group GC. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–20 (quiz 43).PubMedCrossRef Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Group GC. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–20 (quiz 43).PubMedCrossRef
3.
Zurück zum Zitat Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Inter Med. 2004;140(7):518–27.CrossRef Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Inter Med. 2004;140(7):518–27.CrossRef
4.
Zurück zum Zitat Vakil N. Review article: how valuable are proton-pump inhibitors in establishing a diagnosis of gastro-oesophageal reflux disease? Aliment Pharmacol Ther. 2005;22(Suppl 1):64–9 (Epub 2005/07/27).PubMedCrossRef Vakil N. Review article: how valuable are proton-pump inhibitors in establishing a diagnosis of gastro-oesophageal reflux disease? Aliment Pharmacol Ther. 2005;22(Suppl 1):64–9 (Epub 2005/07/27).PubMedCrossRef
5.
Zurück zum Zitat Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38(9):1569–80.PubMedCrossRef Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38(9):1569–80.PubMedCrossRef
6.
Zurück zum Zitat Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD)—acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17(4):537–45.PubMedCrossRef Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD)—acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17(4):537–45.PubMedCrossRef
7.
Zurück zum Zitat Surdea Blaga T, Dumitrascu D, Galmiche JP, Bruley des Varannes S. Functional heartburn: clinical characteristics and outcome. Eur J Gastroenterol Hepatol. 2013;25(3):282–90 (Epub 2012/11/07).PubMedCrossRef Surdea Blaga T, Dumitrascu D, Galmiche JP, Bruley des Varannes S. Functional heartburn: clinical characteristics and outcome. Eur J Gastroenterol Hepatol. 2013;25(3):282–90 (Epub 2012/11/07).PubMedCrossRef
8.
Zurück zum Zitat Eslick GD, Jones MP, Talley NJ. Non-cardiac chest pain: prevalence, risk factors, impact and consulting—a population-based study. Aliment Pharmacol Ther. 2003;17(9):1115–24 (Epub 2003/05/20).PubMedCrossRef Eslick GD, Jones MP, Talley NJ. Non-cardiac chest pain: prevalence, risk factors, impact and consulting—a population-based study. Aliment Pharmacol Ther. 2003;17(9):1115–24 (Epub 2003/05/20).PubMedCrossRef
9.
Zurück zum Zitat Zerbib F, Bruley des Varannes S, Simon M, Galmiche JP. Functional heartburn: definition and management strategies. Curr Gastroenterol Rep. 2012;14(3):181–8.PubMedCrossRef Zerbib F, Bruley des Varannes S, Simon M, Galmiche JP. Functional heartburn: definition and management strategies. Curr Gastroenterol Rep. 2012;14(3):181–8.PubMedCrossRef
10.
Zurück zum Zitat Sweis R, Fox M, Anggiansah A, Wong T. Prolonged, wireless pH-studies have a high diagnostic yield in patients with reflux symptoms and negative 24-h catheter-based pH-studies. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc. 2011;23(5):419–26 (Epub 2011/01/18).CrossRef Sweis R, Fox M, Anggiansah A, Wong T. Prolonged, wireless pH-studies have a high diagnostic yield in patients with reflux symptoms and negative 24-h catheter-based pH-studies. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc. 2011;23(5):419–26 (Epub 2011/01/18).CrossRef
11.
Zurück zum Zitat Slaughter JC, Goutte M, Rymer JA, Oranu AC, Schneider JA, Garrett CG, et al. Caution about overinterpretation of symptom indexes in reflux monitoring for refractory gastroesophageal reflux disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(10):868–74. Slaughter JC, Goutte M, Rymer JA, Oranu AC, Schneider JA, Garrett CG, et al. Caution about overinterpretation of symptom indexes in reflux monitoring for refractory gastroesophageal reflux disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(10):868–74.
12.
Zurück zum Zitat Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58(2):295–309.PubMedCrossRef Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58(2):295–309.PubMedCrossRef
13.
Zurück zum Zitat Savarino E, Zentilin P, Mastracci L, Dulbecco P, Marabotto E, Gemignani L, et al. Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. J Gastroenterol. 2013;48(4):473–82 (Epub 2012/09/25).PubMedCrossRef Savarino E, Zentilin P, Mastracci L, Dulbecco P, Marabotto E, Gemignani L, et al. Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. J Gastroenterol. 2013;48(4):473–82 (Epub 2012/09/25).PubMedCrossRef
14.
Zurück zum Zitat Miner PB Jr, Rodriguez-Stanley S, Proskin HM, Kianifard F, Bottoli I. Tegaserod in patients with mechanical sensitivity and overlapping symptoms of functional heartburn and functional dyspepsia. Curr Med Res Opin. 2008;24(8):2159–72 (Epub 2008/06/20).PubMedCrossRef Miner PB Jr, Rodriguez-Stanley S, Proskin HM, Kianifard F, Bottoli I. Tegaserod in patients with mechanical sensitivity and overlapping symptoms of functional heartburn and functional dyspepsia. Curr Med Res Opin. 2008;24(8):2159–72 (Epub 2008/06/20).PubMedCrossRef
15.
Zurück zum Zitat Rodriguez-Stanley S, Zubaidi S, Proskin HM, Kralstein JR, Shetzline MA, Miner PB Jr. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4(4):442–50 (Epub 2006/04/18). Rodriguez-Stanley S, Zubaidi S, Proskin HM, Kralstein JR, Shetzline MA, Miner PB Jr. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4(4):442–50 (Epub 2006/04/18).
16.
Zurück zum Zitat Ostovaneh MR, Saeidi B, Hajifathalian K, Farrokhi-Khajeh-Pasha Y, Fotouhi A, Mirbagheri SS, et al. Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc. 2014. Ostovaneh MR, Saeidi B, Hajifathalian K, Farrokhi-Khajeh-Pasha Y, Fotouhi A, Mirbagheri SS, et al. Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc. 2014.
17.
18.
Zurück zum Zitat Fenster PE. Evaluation of chest pain: a cardiology perspective for gastroenterologists. Gastroenterol Clin North Am. 2004;33(1):35–40.PubMedCrossRef Fenster PE. Evaluation of chest pain: a cardiology perspective for gastroenterologists. Gastroenterol Clin North Am. 2004;33(1):35–40.PubMedCrossRef
19.
Zurück zum Zitat Park SW, Lee H, Lee HJ, Park JC, Shin SK, Lee SK, et al. Low-dose amitriptyline combined with proton pump inhibitor for functional chest pain. World J Gastroenterol WJG. 2013;19(30):4958–65 (Epub 2013/08/16).CrossRef Park SW, Lee H, Lee HJ, Park JC, Shin SK, Lee SK, et al. Low-dose amitriptyline combined with proton pump inhibitor for functional chest pain. World J Gastroenterol WJG. 2013;19(30):4958–65 (Epub 2013/08/16).CrossRef
20.
Zurück zum Zitat Prakash C, Clouse RE. Long-term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci. 1999;44(12):2373–9.PubMedCrossRef Prakash C, Clouse RE. Long-term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci. 1999;44(12):2373–9.PubMedCrossRef
21.
Zurück zum Zitat Lee H, Kim JH, Min BH, Lee JH, Son HJ, Kim JJ, et al. Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Am J Gastroenterol. 2010;105(7):1504–12.PubMedCrossRef Lee H, Kim JH, Min BH, Lee JH, Son HJ, Kim JJ, et al. Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Am J Gastroenterol. 2010;105(7):1504–12.PubMedCrossRef
22.
Zurück zum Zitat Cannon RO, Quyyumi AA, Mincemoyer R, Stine AM, Gracely RH, Smith WB, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Eng J Med. 1994;330(20):1411–7.CrossRef Cannon RO, Quyyumi AA, Mincemoyer R, Stine AM, Gracely RH, Smith WB, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Eng J Med. 1994;330(20):1411–7.CrossRef
23.
Zurück zum Zitat Cox ID, Hann CM, Kaski JC. Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms. Eur Heart J. 1998;19(2):250–4.PubMedCrossRef Cox ID, Hann CM, Kaski JC. Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms. Eur Heart J. 1998;19(2):250–4.PubMedCrossRef
24.
Zurück zum Zitat Keefe FJ, Shelby RA, Somers TJ, Varia I, Blazing M, Waters SJ, et al. Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study. Pain. 2011;152(4):730–41.PubMedCentralPubMedCrossRef Keefe FJ, Shelby RA, Somers TJ, Varia I, Blazing M, Waters SJ, et al. Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study. Pain. 2011;152(4):730–41.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Doraiswamy PM, Varia I, Hellegers C, Wagner HR, Clary GL, Beyer JL, et al. A randomized controlled trial of paroxetine for noncardiac chest pain. Psychopharmacol Bull. 2006;39(1):15–24 (Epub 2006/10/27).PubMed Doraiswamy PM, Varia I, Hellegers C, Wagner HR, Clary GL, Beyer JL, et al. A randomized controlled trial of paroxetine for noncardiac chest pain. Psychopharmacol Bull. 2006;39(1):15–24 (Epub 2006/10/27).PubMed
26.
Zurück zum Zitat Broekaert D, Fischler B, Sifrim D, Janssens J, Tack J. Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2006;23(3):365–70 (Epub 2006/01/21).PubMedCrossRef Broekaert D, Fischler B, Sifrim D, Janssens J, Tack J. Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2006;23(3):365–70 (Epub 2006/01/21).PubMedCrossRef
27.
Zurück zum Zitat Shapiro M, Shanani R, Taback H, Abramowich D, Scapa E, Broide E. Functional chest pain responds to biofeedback treatment but functional heartburn does not: what is the difference? Eur J Gastroenterol Hepatol. 2012;24(6):708–14.PubMedCrossRef Shapiro M, Shanani R, Taback H, Abramowich D, Scapa E, Broide E. Functional chest pain responds to biofeedback treatment but functional heartburn does not: what is the difference? Eur J Gastroenterol Hepatol. 2012;24(6):708–14.PubMedCrossRef
28.
Zurück zum Zitat Chiarioni G, Whitehead WE. The role of biofeedback in the treatment of gastrointestinal disorders. Nat Clin Pract Gastroenterol Hepatol. 2008;5(7):371–82.PubMedCrossRef Chiarioni G, Whitehead WE. The role of biofeedback in the treatment of gastrointestinal disorders. Nat Clin Pract Gastroenterol Hepatol. 2008;5(7):371–82.PubMedCrossRef
29.
Zurück zum Zitat Hjelland IE, Svebak S, Berstad A, Flatabo G, Hausken T. Breathing exercises with vagal biofeedback may benefit patients with functional dyspepsia. Scand J Gastroenterol. 2007;42(9):1054–62 (Epub 2007/08/22).PubMedCrossRef Hjelland IE, Svebak S, Berstad A, Flatabo G, Hausken T. Breathing exercises with vagal biofeedback may benefit patients with functional dyspepsia. Scand J Gastroenterol. 2007;42(9):1054–62 (Epub 2007/08/22).PubMedCrossRef
30.
Zurück zum Zitat Gasiorowska A, Navarro-Rodriguez T, Dickman R, Wendel C, Moty B, Powers J, et al. Clinical trial: the effect of Johrei on symptoms of patients with functional chest pain. Aliment Pharmacol Ther. 2009;29(1):126–34 (Epub 2008/10/24).PubMedCrossRef Gasiorowska A, Navarro-Rodriguez T, Dickman R, Wendel C, Moty B, Powers J, et al. Clinical trial: the effect of Johrei on symptoms of patients with functional chest pain. Aliment Pharmacol Ther. 2009;29(1):126–34 (Epub 2008/10/24).PubMedCrossRef
31.
Zurück zum Zitat Jonsbu E, Dammen T, Morken G, Moum T, Martinsen EW. Short-term cognitive behavioral therapy for non-cardiac chest pain and benign palpitations: a randomized controlled trial. J Psychosom Res. 2011;70(2):117–23 (Epub 2011/01/26).PubMedCrossRef Jonsbu E, Dammen T, Morken G, Moum T, Martinsen EW. Short-term cognitive behavioral therapy for non-cardiac chest pain and benign palpitations: a randomized controlled trial. J Psychosom Res. 2011;70(2):117–23 (Epub 2011/01/26).PubMedCrossRef
32.
Zurück zum Zitat Rao SS, Mudipalli RS, Mujica V, Utech CL, Zhao X, Conklin JL. An open-label trial of theophylline for functional chest pain. Dig Dis Sci. 2002;47(12):2763–8.PubMedCrossRef Rao SS, Mudipalli RS, Mujica V, Utech CL, Zhao X, Conklin JL. An open-label trial of theophylline for functional chest pain. Dig Dis Sci. 2002;47(12):2763–8.PubMedCrossRef
33.
Zurück zum Zitat Jones H, Cooper P, Miller V, Brooks N, Whorwell PJ. Treatment of non-cardiac chest pain: a controlled trial of hypnotherapy. Gut. 2006;55(10):1403–8.PubMedCentralPubMedCrossRef Jones H, Cooper P, Miller V, Brooks N, Whorwell PJ. Treatment of non-cardiac chest pain: a controlled trial of hypnotherapy. Gut. 2006;55(10):1403–8.PubMedCentralPubMedCrossRef
34.
Zurück zum Zitat Clouse RE, Lustman PJ, Eckert TC, Ferney DM, Griffith LS. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology. 1987;92(4):1027–36.PubMed Clouse RE, Lustman PJ, Eckert TC, Ferney DM, Griffith LS. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology. 1987;92(4):1027–36.PubMed
35.
Zurück zum Zitat Cook IJ, Dent J, Shannon S, Collins SM. Measurement of upper esophageal sphincter pressure. Effect of acute emotional stress. Gastroenterology. 1987;93(3):526–32 (Epub 1987/09/01).PubMed Cook IJ, Dent J, Shannon S, Collins SM. Measurement of upper esophageal sphincter pressure. Effect of acute emotional stress. Gastroenterology. 1987;93(3):526–32 (Epub 1987/09/01).PubMed
36.
Zurück zum Zitat Kumar AR, Katz PO. Functional esophageal disorders: a review of diagnosis and management. Expert Rev Gastroenterol Hepatol. 2013;7(5):453–61 (Epub 2013/08/01).PubMedCrossRef Kumar AR, Katz PO. Functional esophageal disorders: a review of diagnosis and management. Expert Rev Gastroenterol Hepatol. 2013;7(5):453–61 (Epub 2013/08/01).PubMedCrossRef
37.
Zurück zum Zitat Selleslagh M, van Oudenhove L, Pauwels A, Tack J, Rommel N. The complexity of globus: a multidisciplinary perspective. Nat Rev Gastroenterol Hepatol. 2013. Selleslagh M, van Oudenhove L, Pauwels A, Tack J, Rommel N. The complexity of globus: a multidisciplinary perspective. Nat Rev Gastroenterol Hepatol. 2013.
38.
Zurück zum Zitat Jeon HK, Kim GH, Choi MK, Cheong JH, Baek DH, Lee GJ, et al. Clinical predictors for response to proton pump inhibitor treatment in patients with globus. J Neurogastroenterol Motil. 2013;19(1):47–53.PubMedCentralPubMedCrossRef Jeon HK, Kim GH, Choi MK, Cheong JH, Baek DH, Lee GJ, et al. Clinical predictors for response to proton pump inhibitor treatment in patients with globus. J Neurogastroenterol Motil. 2013;19(1):47–53.PubMedCentralPubMedCrossRef
39.
Zurück zum Zitat Kirch S, Gegg R, Johns MM, Rubin AD. Globus pharyngeus: effectiveness of treatment with proton pump inhibitors and gabapentin. Ann Otol Rhinol Laryngol. 2013;122(8):492–5.PubMed Kirch S, Gegg R, Johns MM, Rubin AD. Globus pharyngeus: effectiveness of treatment with proton pump inhibitors and gabapentin. Ann Otol Rhinol Laryngol. 2013;122(8):492–5.PubMed
40.
Zurück zum Zitat Kiebles JL, Kwiatek MA, Pandolfino JE, Kahrilas PJ, Keefer L. Do patients with globus sensation respond to hypnotically assisted relaxation therapy? A case series report. Dis Esophagus. 2010;23(7):545–53 (Epub 2010/05/13).PubMedCrossRef Kiebles JL, Kwiatek MA, Pandolfino JE, Kahrilas PJ, Keefer L. Do patients with globus sensation respond to hypnotically assisted relaxation therapy? A case series report. Dis Esophagus. 2010;23(7):545–53 (Epub 2010/05/13).PubMedCrossRef
41.
Zurück zum Zitat You LQ, Liu J, Jia L, Jiang SM, Wang GQ. Effect of low-dose amitriptyline on globus pharyngeus and its side effects. World J Gastroenterol WJG. 2013;19(42):7455–60.CrossRef You LQ, Liu J, Jia L, Jiang SM, Wang GQ. Effect of low-dose amitriptyline on globus pharyngeus and its side effects. World J Gastroenterol WJG. 2013;19(42):7455–60.CrossRef
42.
Zurück zum Zitat Deary IJ, Wilson JA. Problems in treating globus pharyngis. Clin Otolaryngol Allied Sci. 1994;19(1):55–60 (Epub 1994/02/01).PubMedCrossRef Deary IJ, Wilson JA. Problems in treating globus pharyngis. Clin Otolaryngol Allied Sci. 1994;19(1):55–60 (Epub 1994/02/01).PubMedCrossRef
43.
Zurück zum Zitat Tokashiki R, Okamoto I, Funato N, Suzuki M. Rikkunshito improves globus sensation in patients with proton-pump inhibitor-refractory laryngopharyngeal reflux. World J Gastroenterol WJG. 2013;19(31):5118–24.CrossRef Tokashiki R, Okamoto I, Funato N, Suzuki M. Rikkunshito improves globus sensation in patients with proton-pump inhibitor-refractory laryngopharyngeal reflux. World J Gastroenterol WJG. 2013;19(31):5118–24.CrossRef
44.
Zurück zum Zitat Nahata M, Muto S, Oridate N, Ohnishi S, Nakagawa K, Sadakane C, et al. Impaired ghrelin signaling is associated with gastrointestinal dysmotility in rats with gastroesophageal reflux disease. Am J Physiol Gastrointest liver Physiol. 2012;303(1):G42–53 (Epub 2012/04/21).PubMedCentralPubMedCrossRef Nahata M, Muto S, Oridate N, Ohnishi S, Nakagawa K, Sadakane C, et al. Impaired ghrelin signaling is associated with gastrointestinal dysmotility in rats with gastroesophageal reflux disease. Am J Physiol Gastrointest liver Physiol. 2012;303(1):G42–53 (Epub 2012/04/21).PubMedCentralPubMedCrossRef
45.
Zurück zum Zitat Khalil HS, Reddy VM, Bos-Clark M, Dowley A, Pierce MH, Morris CP, et al. Speech therapy in the treatment of globus pharyngeus: how we do it. Clin Otolaryngol Off J ENT-UK Off J Neth Soc Oto-Rhino-Laryngol Cerv-Fac Surg. 2011;36(4):388–92 (Epub 2011/08/19). Khalil HS, Reddy VM, Bos-Clark M, Dowley A, Pierce MH, Morris CP, et al. Speech therapy in the treatment of globus pharyngeus: how we do it. Clin Otolaryngol Off J ENT-UK Off J Neth Soc Oto-Rhino-Laryngol Cerv-Fac Surg. 2011;36(4):388–92 (Epub 2011/08/19).
46.
Zurück zum Zitat Millichap F, Lee M, Pring T. A lump in the throat: should speech and language therapists treat globus pharyngeus? Disabil Rehabil. 2005;27(3):124–30 (Epub 2005/04/13).PubMedCrossRef Millichap F, Lee M, Pring T. A lump in the throat: should speech and language therapists treat globus pharyngeus? Disabil Rehabil. 2005;27(3):124–30 (Epub 2005/04/13).PubMedCrossRef
Metadaten
Titel
Functional Esophageal Disorders: Pharmacological Options
verfasst von
Gehanjali Amarasinghe
Daniel Sifrim
Publikationsdatum
01.08.2014
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 12/2014
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-014-0272-y

Weitere Artikel der Ausgabe 12/2014

Drugs 12/2014 Zur Ausgabe